248 related articles for article (PubMed ID: 23816498)
21. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier.
Jennings L; Molloy O; Quinlan C; Kelly G; O'Kane M
Int J Dermatol; 2017 Jun; 56(6):e128-e129. PubMed ID: 28239847
[No Abstract] [Full Text] [Related]
22. [Anakinra therapy in a patient with multifocal pyoderma gangrenosum and hidradenitis suppurativa].
Oymanns M; Kreuter A; Assaf C
Hautarzt; 2021 May; 72(5):435-438. PubMed ID: 33095334
[TBL] [Abstract][Full Text] [Related]
23. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis.
Murphy B; Morrison G; Podmore P
Int J Colorectal Dis; 2015 Aug; 30(8):1139-40. PubMed ID: 25564349
[No Abstract] [Full Text] [Related]
24. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab.
De Wet J; Jordaan HF; Kannenberg SM; Tod B; Glanzmann B; Visser WI
Dermatol Online J; 2017 Dec; 23(12):. PubMed ID: 29447652
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
26. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?
Garzorz N; Papanagiotou V; Atenhan A; Andres C; Eyerich S; Eyerich K; Ring J; Brockow K
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):141-3. PubMed ID: 25070077
[No Abstract] [Full Text] [Related]
27. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone.
Staub J; Pfannschmidt N; Strohal R; Braun-Falco M; Lohse P; Goerdt S; Leverkus M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2243-7. PubMed ID: 25352307
[TBL] [Abstract][Full Text] [Related]
28. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
Sockolov ME; Alikhan A; Zargari O
J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
[TBL] [Abstract][Full Text] [Related]
29. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
30. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab.
Montes-Romero JA; Callejas-Rubio JL; Sánchez-Cano D; González-Martínez FJ; Navas-Parejo A; Ortego-Centeno N
Eur J Intern Med; 2008 Oct; 19(6):e32-3. PubMed ID: 18848164
[No Abstract] [Full Text] [Related]
31. Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
Tekin B; Salman A; Ergun T
Indian J Dermatol Venereol Leprol; 2017; 83(5):615-617. PubMed ID: 28731016
[No Abstract] [Full Text] [Related]
32. Familial Mediterranean fever patients with hidradenitis suppurativa.
Vural S; Gundogdu M; Kundakci N; Ruzicka T
Int J Dermatol; 2017 Jun; 56(6):660-663. PubMed ID: 28194777
[TBL] [Abstract][Full Text] [Related]
33. Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy.
Pedraz J; Peñas PF; Garcia-Diez A
J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1500-1. PubMed ID: 18482325
[No Abstract] [Full Text] [Related]
34. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.
Yamanaka K
J Dermatol; 2024 Feb; 51(2):172-179. PubMed ID: 38009911
[TBL] [Abstract][Full Text] [Related]
35. Management of recalcitrant hidradenitis suppurativa with ustekinumab.
Sharon VR; Garcia MS; Bagheri S; Goodarzi H; Yang C; Ono Y; Maverakis E
Acta Derm Venereol; 2012 May; 92(3):320-1. PubMed ID: 22101775
[No Abstract] [Full Text] [Related]
36. Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction.
Company-Quiroga J; Alique-García S; Martínez-Morán C; Khedaoui R; Romero-Maté A; Borbujo J
Indian J Dermatol Venereol Leprol; 2019; 85(4):422-425. PubMed ID: 31115357
[No Abstract] [Full Text] [Related]
37. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient.
Katsanos KH; Christodoulou DK; Tsianos EV
Am J Gastroenterol; 2002 Aug; 97(8):2155-6. PubMed ID: 12190206
[No Abstract] [Full Text] [Related]
38. Secukinumab for PASS syndrome: A new choice for therapeutic challenge?
Li M; Xiang H; Liang Y; Xue L; Zhou X; Yang L; Liu H; Yang M; Tang J; Li W
Dermatol Ther; 2022 Jul; 35(7):e15507. PubMed ID: 35419914
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris.
Flora A; Frew JW
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e372-e374. PubMed ID: 35986694
[No Abstract] [Full Text] [Related]
40. Novel PSTPIP1 gene mutation in pyoderma gangrenosum, acne and suppurative hidradenitis syndrome.
Saito N; Minami-Hori M; Nagahata H; Nozaki H; Iinuma S; Igawa S; Kanno K; Kishibe M; Kanazawa N; Ishida-Yamamoto A
J Dermatol; 2018 Aug; 45(8):e213-e214. PubMed ID: 29575118
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
